ABSTRACT
Vacina contra hepatite B, produzida no Instituto Butantan em levedura recombinante, foi administrada em dois grupos de voluntarios adultos (I e II) seguindo dois esquemas diferentes de imunizacao. No primeiro ensaio (doses de 10 ug e esquema de vacinacao de 0, 1, 3 meses). 106 individuos completaram p programa de imunizacao proposto...
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Hepatitis B Vaccines/adverse effects , Hepatitis B/immunology , Immunization Schedule , VaccinationABSTRACT
Hepatitis B is a serious viral infection that represents a parenterally and sexually transmitted disease of wordwide importance. There is no effective treatment being vaccination the only real way to control this infection. Recombinant DNA technology has been successfully used for development of a safe and effective vaccine agaiinst Hepatitis B. Among different expression systems yeast Saccharomyces cerevisiae is considered appropriate for efficient synthesis of Hepatitis Bsurface antigen (HBsAg) and large-scale production of recombinant vaccine. In spite of many benefits of commercially available recombinant vaccines they have to be improved for immunogenicity. Supplementing HBsAg with preS epitopes is the prospective way to increase the potency of yeast-derived recombinant vaccine.